Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial

Drugs

Volumn 55, Issue SUPPL. 1, 1998, Pages 23-30

  Rinne, U K ^a   Bracco, F ^b   Chouza, C ^c   Dupont, E ^d   Gershanik, O ^e   Marti Masso, J F ^f   Montastruc, J L ^g   Marsden, C D ^h  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF PADOVA   (Italy)

^c HOSPITAL DE CLÍNICAS   (Uruguay)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e HOSPITAL FRANCÉS   (Argentina)

^f Hospital Nuestra Senora de Aranzazu   (Spain)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

ACTIVITIES OF DAILY LIVING; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; ERGOLINES; FEMALE; HUMANS; LEVODOPA; LINEAR MODELS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PARKINSON DISEASE; TIME FACTORS;

EID: 0031985731     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855001-00004     Document Type: Conference Paper

References (21)

1. Fariello R, Carfagna N, Buonamici M, et al. Cabergoline: a long acting D2 agonist with antiparkinsonian properties: preclinical studies [abstract]. Ann Neurol 1991; 30: 258
2. Strolin-Benedetti M, Cocchiara G, Battaglia R, et al. Pharmacokinetic and metabolic pattern of cabergoline, a long-acting dopamine agonist in healthy volunteers. Presented at the 10th International Symposium on Parkinson's Disease; 1991 Oct 19; Tokyo
3. Ferrari C, Barberi C, Caldara R, et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63: 941-5
4. Lera G, Vaamonde J, Muruzabal LM, et al. Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Ann Neurol 1990; 28: 593-4
5. Lees AJ. L-Dopa treatment and Parkinson's disease. Q J Med 1986; 59: 535-47
6. Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonism and the complications of longterm levodopa therapy. Neurology 1979; 29: 1253-60
7. Rinne UK. Treatment of Parkinson's disease: problems with a progressing disease. J Neural Transm 1981; 51: 161-74
8. Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 36: 27-31, 1994
9. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986; 49: 853-60
10. Rodriguez M, Lera G, Vaamonde J, et al. Motor response to apomorphine and levodopa in asymetric Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 562-6
11. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987; 37: 826-8
12. Stern G, Lees A. Long term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease. In: Yahr MD, Bergmann KJ, editors. Adv Neurol Vol. 45. New York: Raven Press, 1986: 525-7
13. Hoehn M. Using bromocriptine to manage the inadequacies of L-Dopa therapy. In: Fahn S, Marsden CD, Jenner P, et al., editors. Recent developments in Parkinson's disease. New York: Raven Press, 293-301, 1985
14. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997; 48: 363-88
15. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993; 43 Suppl. 6: 547-52
16. van Dijk JG, Haan J, Zwinderman K, et al. Autonomic nervous system dysfunction in parkinson's disease: relationships with age, medication, duration and severity. J Neurol Neurosurg Psychiatry 1993; 56: 1090-5
17. The Parkinson Study Group. The effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
18. Lees AJ, and the Parkinson's Disease Research Group. Comparisons of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson's disease. BMJ 1995; 311: 1602-7
19. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989; 39: 336-9
20. Montastruc JL, Rascol O, Senard JM, et al. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 1994; 57: 1034-8
21. Giménez-Roldán S, Tolosa E, Burguera JA, et al. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 1997; 20: 67-76